Menu

Bees’ Molecular Responses to Neonicotinoids Determined

Researchers pinpoint a protein that can metabolize at least one of the insecticides, highlighting a route to identifying compounds that are friendlier to the critical pollinators.

Mar 22, 2018
Catherine Offord

BAYER BEE CARE CENTERPopulations of honeybees have crashed in recent years, and many researchers have pointed the blame at a class of widely used insecticides called neonicotinoids. But studies have shown that not all the compounds are equally toxic to these critical pollinators, suggesting that there might be variation in how the insects metabolize them.

Now, a team of academic and industry scientists in Europe have traced this differing sensitivity to an enzyme in the cytochrome P450 superfamily of proteins that can metabolize at least one neonicotinoid into a less toxic derivative. The findings, published today (March 22) in Current Biology, raise the possibility of identifying bee-friendly pesticides based on their vulnerability to detoxification via this mechanism.

“They’ve provided an incredibly useful service in illuminating how honeybees process toxins,” says May Berenbaum, an entomologist at the University of Illinois at Urbana-Champaign who was not involved in the work. Given bees’ routine exposures to pesticides as they forage for food and pollinate crops, “it’s incredibly important to know this.”

Neonicotinoids target nicotinic acetylcholine receptors (nAChRs) in the insect central nervous system. While several of the seven commercially available compounds are classified by the Environmental Protection Agency as highly toxic to honeybees if ingested or touched, two are considered only mildly toxic—a distinction that’s often overlooked in the debate about the compounds’ use, notes coauthor Ralf Nauen, an insect toxicologist at Germany-based Bayer CropScience, a major neonicotinoid manufacturer. Usually, “they’re all thrown in the same bucket,” he says.

See “Field Studies Confirm Neonicotinoids’ Harm to Bees

A few years ago, Nauen and his colleagues set out to get to the bottom of these differences. In collaboration with researchers at the University of Exeter and agricultural research institute Rothamsted Research in the U.K., the Bayer team focused on two compounds: the highly toxic imidacloprid and the slightly toxic thiacloprid. Combining new data with previous experiments, the researchers found in their latest study that honeybees (Apis mellifera) and bumble bees (Bombus terrestis) could survive touching or ingesting many hundreds of times higher doses of thiacloprid than of imidacloprid.

BAYER BEE CARE CENTER This variation was not due to differences in how the compounds interact with their protein target, the team observed: binding experiments revealed that both neonicotinoids have a similar affinity for nAChR in vitro. So the researchers turned to a class of proteins involved in metabolism, the cytochrome P450s.

The P450 superfamily is represented in almost all living organisms, and contains multiple enzymes that break down toxins. Previous research had shown that broadly inhibiting P450 enzymes greatly increases honeybees’ sensitivity to thiacloprid, but not to imidacloprid, implicating a role for at least some of the proteins in mitigating neonicotinoid toxicity. “That suggested we should really focus in on this group of enzymes,” study coauthor Chris Bass, an entomologist at the University of Exeter, tells The Scientist.

To identify relevant P450s, the researchers created 27 different insect cell lines, each expressing a unique honeybee P450 gene. Then, they incubated each cell line with a helping of either mildly toxic thiacloprid or super toxic imidacloprid. While none of the cells managed to efficiently break down imidacloprid, one cell line, containing a P450 gene called CYP9Q3, metabolized almost all of its thiacloprid dose in less than 60 minutes, Nauen says. The researchers found that these cells were converting the neonicotinoid into 5-hydroxy thiacloprid—a related, but substantially less toxic, compound.

Using Drosophila to transgenically express CYP9Q3, the team demonstrated that this mechanism is sufficient to confer thiacloprid resistance. “Wildtype flies, not having this honeybee gene, are normally susceptible to thiacloprid—it’s toxic to them,” explains Nauen. “But when the flies express CYP9Q3, the honeybee gene, they become tolerant.”

The mechanism isn’t limited to honeybees, the researchers found. Bumble bees possess a similar detoxification system thanks to a CYP9Q3 ortholog that the team has named CYP9Q4. “It’s quite an important result,” says Bass, “because it suggests that, at least in social bees, this system is quite conserved.” More recent, unpublished data suggest that some solitary bees may also use P450-based mechanisms to break down neonicotinoids, he adds.

See “Neonicotinoids May Harm Wild Bees

Geraldine Wright, an insect neuroethologist at Newcastle University who didn’t take part in the study, notes that the findings contribute a valuable piece of the neonicotinoid puzzle. “These guys have published something that a lot of other people were interested in trying to do,” she says. “It’s quite important if you’re trying to use insecticides in a situation where pollinators might be affected.”

The team’s transgenic fruit fly system could be a useful tool for other researchers studying pollinator responses to neonicotinoids. As well as providing a better-understood genetic background to work with, the screening approach removes the immediate need for a bee, Nauen explains. “Honeybees are only available for a few months a year,” he says. “This Drosophila brings us in a position to test all year round.”

The work represents just a step on the road to understanding neonicotinoids’ real-world effects on bee health. For a start, bees’ exposures to a single pesticide compound is not a hugely “field-relevant” scenario, says Wright. “Very often these compounds are not used in isolation on crops,” she explains. “It’d be good to know, when these compounds are mixed with other compounds found in pesticides [such as fungicides], how that affects the efficiency of these P450 enzymes to detoxify neonicotinoids.” The Drosophila model offers the opportunity to test that, she adds.

BAYER BEE CARE CENTERThe findings should also be validated with research in the field, where bees forage for their food, engage behaviorally with other bees, and encounter widely varying levels of different pesticides, says ecologist Maj Rundlöf of Lund University in Sweden. “Models can be useful . . . but I’m not sure a study like this can give us the definitive answer that thiacloprid is preferred over imidacloprid.” Ideally, she adds, further research would be performed by a team that doesn’t have vested interests in the neonicotinoid-manufacturing business.

Berenbaum emphasizes that the larger debate on neonicotinoid usage in agriculture needs to be understood in the context of additional bee stressors, from other pesticide classes to large-scale ecological disruptions such as habitat loss. “It’s an enormously complicated situation out there,” she says. “Focusing just on neonics, and thinking that banning neonics is going to fix things, I think really underestimates the magnitude of the problems that bees are dealing with.”

C. Manjon et al., “Unravelling the molecular determinants of bee sensitivity to neonicotinoid insecticides,” Current Biology, doi:10.1016/j.cub.2018.02.045, 2018.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.